Old Web
English
Sign In
Acemap
>
authorDetail
>
S Choi
S Choi
Celgene
Neutropenia
Placebo
Lupus erythematosus
Tolerability
Medicine
3
Papers
7
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
379 A phase 2, randomized, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics & pharmacogenetics of CC-220 in subjects with SLE
2017
Journal of Investigative Dermatology
Victoria P. Werth
R. Furie
Douglas Hough
Shimon Korish
Michael Weiswasser
A. Azarian
Peter H. Schafer
Nikolay Delev
S Choi
Show All
Source
Cite
Save
Citations (0)
SAT0225 Cereblon modulator CC-220 decreases naÏve and memory B cells and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients: exposure-response results from a phase 2A proof of concept study
2017
Annals of the Rheumatic Diseases
A. Gaudy
Ying Ye
Shimon Korish
Douglas Hough
Michael Weiswasser
S Choi
Richard Furie
Victoria P. Werth
Peter H. Schafer
Show All
Source
Cite
Save
Citations (3)
SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus
2017
Annals of the Rheumatic Diseases
Victoria P. Werth
Richard Furie
Shimon Korish
Michael Weiswasser
A Azaryan
Peter H. Schafer
Nikolay Delev
S Choi
Douglas Hough
Show All
Source
Cite
Save
Citations (4)
1